Revenue

FDA clears Phase IIb trial for CS1, an epigenetic drug aiming to reverse PAH damage, not just manage symptoms, signaling a major market and patient shift.

Toro's acquisition of Tornado isn't just about new machinery; it's a calculated move to capture the booming, safety-critical underground excavation market.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Global Ship Lease's steady dividend is more than investor news; it reveals deep insights into containership market health and strategic resilience.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

A junior miner's historic regulatory win in Oregon could set a new precedent for resource development, balancing economic promise with environmental rigor.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

Latham Group hires building products veteran Sean Gadd to lead its next wave of growth. Can a playbook that dominated fiber cement convert the pool industry?

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

As it readies for a SPAC merger, quantum leader Infleqtion hires a top aerospace veteran to scale its sensing unit for defense and commercial markets.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

A food-tech firm's pivot from quiet operator to public force reveals a savvy digital strategy, a key US acquisition, and a plan to dominate the 'better-for-you' market.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A Japanese EdTech firm is offering unlimited free English lessons in Brazil. Is this a savvy market capture or a high-risk gamble in a crowded space?

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

A cub’s rescue reveals more than a conservation win; it showcases China's massive investment in 'ecological civilization' as a core economic strategy.

WEP's deployment of 700 inspection systems in Missouri showcases its execution, but can it leverage this win in a competitive multi-billion dollar market?

A 40-year-old San Antonio dermatology group joins a corporate network, highlighting a national trend. What does this mean for local patients and physicians?